Reviewing the impact of obesity on inflammatory bowel disease and considerations for optimizing management.
Curr Opin Gastroenterol
; 40(4): 268-275, 2024 Jul 01.
Article
de En
| MEDLINE
| ID: mdl-38662340
ABSTRACT
PURPOSE OF REVIEW This review examines the complex relationship between obesity and inflammatory bowel disease (IBD), encompassing their potentially shared pathogenesis, the impact of obesity on the natural history and treatment outcomes of IBD, and the management of obesity in the patient with IBD. RECENT FINDINGS:
Obesity represents a state of chronic inflammation that may not only contribute to IBD pathogenesis, but also influence disease progression, complications, and response to treatment. Increased visceral adiposity may carry negative prognostic implications for disease and treatment-specific outcomes. Antiobesity medications, endoscopic bariatric therapies, and even bariatric surgery may be effective and well tolerated in selected patients with IBD.SUMMARY:
The intersection of obesity and IBD presents a significant clinical challenge, with obesity influencing the natural history of IBD and potentially affecting treatment efficacy. As obesity prevalence among IBD patients rises, a tailored approach to management is crucial, taking into account the individualized risks and benefits of various treatment strategies, including lifestyle interventions, pharmacotherapy, endoscopic procedures, and bariatric surgery.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Maladies inflammatoires intestinales
/
Chirurgie bariatrique
/
Obésité
Limites:
Humans
Langue:
En
Journal:
Curr Opin Gastroenterol
Sujet du journal:
GASTROENTEROLOGIA
Année:
2024
Type de document:
Article